BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day o ...

Core Viewpoint - Greenland Technologies Holding Corporation has successfully closed its public offering of 5,083,330 units at a price of $1.20 per unit, raising approximately $6.1 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - Each unit consists of one ordinary share and four-fifths of one warrant, with each whole warrant exercisable for one ordinary share [1]. - The warrants are immediately exercisable at an exercise price of $1.20 per share and will expire three years from the date of issuance [2]. - The offering was conducted on a firm commitment basis, with Joseph Stone Capital, LLC serving as the sole underwriter [3]. Group 2: Regulatory and Legal Information - The offering was made pursuant to a registration statement on Form S-1, which was declared effective by the SEC on January 26, 2026 [4]. - A final prospectus related to the offering has been filed with the SEC and is available on the SEC's website [4]. Group 3: Company Overview - Greenland Technologies Holding Corporation is a technology developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling machineries and vehicles [6].

Core Viewpoint - MetaVia Inc. has successfully closed an underwritten public offering, raising approximately $9.3 million for the development of its cardiometabolic disease treatments [1][3]. Group 1: Offering Details - The public offering included 3,005,574 shares of common stock and 9,016,722 warrants (4,508,361 Series C Warrants and 4,508,361 Series D Warrants) at a price of $3.10 per share [2]. - The Series C and Series D Warrants are immediately exercisable at an exercise price of $3.10, with Series C expiring in five years and Series D in two years [2]. - The Series D Warrants can be called by the company following a positive data readout from its Phase 1b Part III clinical trial for DA-1726 [2]. Group 2: Financial Implications - If fully exercised, the warrants could yield up to approximately $28.0 million in future gross proceeds [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes, specifically to continue the clinical development of DA-1726 for obesity treatment [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [7]. - DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, showing potential for superior weight loss and glucose control [7]. - Vanoglipel (DA-1241) is a GPR119 agonist that has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [7].

Core Viewpoint - ITT Inc. has successfully closed a public offering of 8,050,000 shares of common stock, raising approximately $1.31 billion in net proceeds, which will primarily fund the acquisition of SPX FLOW, Inc. [1][2] Group 1: Offering Details - The public offering price was set at $167.00 per share, including the full exercise of the underwriters' option to purchase an additional 1,050,000 shares [1] - Goldman Sachs & Co. LLC and UBS Investment Bank served as lead book-running managers for the offering, with several other banks acting as additional bookrunners and co-managers [3] Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund a portion of the acquisition of SPX FLOW, Inc. If the acquisition does not proceed, the funds will be allocated for general corporate purposes [2] Group 3: Company Overview - ITT is a diversified manufacturer specializing in critical components and customized technology solutions for transportation, industrial, and energy markets, with a global presence in over 35 countries [6]

Core Points - Salarius Pharmaceuticals Inc. shares increased by 23.65% in after-hours trading, closing at $1.21, following the announcement of pricing details for its public offering [1] - The stock had previously dropped 51% during regular trading, closing at $0.98 [1] Offering Details - Salarius announced a public offering aimed at raising approximately $7 million in gross proceeds before fees [2] - The offering includes 2.51 million common stock shares and pre-funded warrants for 2.15 million shares, priced at $1.50 per share [2] Warrant Structure and Terms - The exercise price for both Series A and Series B warrants is set at $1.50 [3] - Series B warrants have a one-year exercise window, while Series A warrants can be exercised for five years after issuance [3] - The warrants feature fixed pricing with no variable pricing elements [3] Merger-Contingent Closing - The closing of the offering is contingent upon the completion of Salarius' proposed business combination with Decoy Therapeutics Inc., expected to occur on Wednesday [4] - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering [4] - Proceeds from the offering will be used to fund research programs, repay Decoy's promissory notes, and cover working capital needs [4] Stock Performance - Year-to-date, Salarius' stock has decreased by 96.25% [5] - The company has a market capitalization of $1.03 million and an average daily trading volume of 318,090 shares [5] - Benzinga Edge Stock Rankings indicate a negative price trend for SLRX across all time frames [5]

Core Viewpoint - Apogee Therapeutics, Inc. has announced a public offering of 6,951,221 shares of common stock priced at $41.00 per share, aiming to raise approximately $300 million before expenses [1]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 365,853 shares at a price of $40.99999 per warrant, with an exercise price of $0.00001 per share [1]. - The offering is expected to close on October 10, 2025, subject to customary closing conditions [1]. - Underwriters have an option to purchase an additional 1,097,561 shares at the public offering price within 30 days [1]. Group 2: Underwriters - Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen are acting as joint book-running managers for the offering, while BTIG serves as a passive bookrunner [2]. Group 3: Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including treatments for Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5]. - The company's lead program, APG777, targets Atopic Dermatitis, which is noted as a large and under-penetrated market [5]. - Apogee aims to achieve best-in-class profiles through its antibody programs by addressing limitations of existing therapies and optimizing properties such as half-life [5].

Core Viewpoint - Apogee Therapeutics, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the intention to utilize the proceeds for various research and development activities, including clinical trials and manufacturing [1][2]. Group 1: Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund preclinical studies, clinical trials, manufacturing, and commercial readiness activities for the company's antibody programs [2]. - Additional uses include research and development activities, capital expenditures, working capital, and general corporate purposes [2]. Group 3: Company Overview - Apogee Therapeutics is focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, and Chronic Obstructive Pulmonary Disease [6]. - The company's lead program, APG777, is aimed at treating Atopic Dermatitis, which is identified as a significant and under-penetrated market [6]. - Apogee's antibody programs are designed to enhance existing therapies by targeting established mechanisms and optimizing properties through advanced engineering [6].

Core Viewpoint - Immuneering Corporation has announced a proposed underwritten public offering of its Class A common stock and a concurrent private placement with Sanofi for $25 million, aimed at advancing its oncology product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes shares of Class A common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase an additional 15% of the offered shares [1]. - Sanofi will purchase $25 million worth of Immuneering's Class A common stock or non-voting Class B common stock at the public offering price, in a private placement expected to close concurrently with the public offering [1][2]. - The offering is subject to market conditions and the private placement is contingent upon the closing of the public offering [1]. Group 2: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to advance preclinical and clinical development of product candidates, as well as for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on August 20, 2025 [3]. - A preliminary prospectus supplement will be filed with the SEC, and copies will be available through the underwriters [3][7]. Group 4: Securities Registration - The shares sold in the private placement will not be registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].

Group 1 - Sana Biotechnology, Inc. has successfully closed the sale of 3,358,208 shares of its common stock at a price of $3.35 per share, resulting in total gross proceeds of approximately $86.3 million [1] - The offering was part of a previously announced underwritten public offering that closed on August 8, 2025, and included the full exercise of the underwriters' option to purchase additional shares [1] - The joint book-running managers for the offering included Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen [2] Group 2 - The offering was conducted under a Registration Statement on Form S-3, which was previously filed and declared effective by the SEC [3] - Final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are accessible through the SEC's website [3] - Sana Biotechnology is focused on creating and delivering engineered cells as medicines for patients, with operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5]

Company Overview - iSpecimen Inc. operates an online global marketplace connecting scientists with healthcare specimen providers for medical research [6] - The company utilizes proprietary cloud-based technology to facilitate the search for biospecimens and patients across a network of healthcare organizations [6] Recent Offering - On July 25, 2025, iSpecimen announced the closing of an underwritten public offering of 5,714,283 shares at a price of $0.70 per share, generating approximately $4 million in gross proceeds [2][3] - The offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [3] Use of Proceeds - The net proceeds from the offering will be allocated as follows: $1.5 million for marketing and advertising services from IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital and general corporate purposes [3] Regulatory Compliance - The securities offered are pursuant to a registration statement on Form S-1, which was declared effective by the SEC on July 23, 2025 [4]